{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:59:06Z","timestamp":1790744346351,"version":"4.1.0"},"reference-count":71,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IRC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, representing a major public health challenge. Although low-dose computed tomography is currently the standard screening method for high-risk individuals to reduce mortality, its clinical performance is limited by false-positive findings and restricted accessibility. Emerging biomarker-based liquid biopsy offers a promising non-invasive approach for cancer detection. This narrative review provides a critical overview and evaluation of clinically endorsed liquid biopsy applications for guiding treatment in advanced-stage lung cancer, as well as investigational advances in liquid biopsy for early cancer detection. We also address challenges of current liquid biopsy technologies, the integration of artificial intelligence, implementation improvements, and future perspectives for their adoption into routine clinical practice. To complement this narrative review, a structured search of the ClinicalTrials.gov registry was performed to identify clinical trials evaluating liquid biopsy in lung cancer. Current evidence supports the clinical use of liquid biopsy for molecular profiling and treatment selection in advanced non-small cell lung cancer (NSCLC), whereas its application in early detection, screening, and minimal residual disease (MRD)-guided management remains investigational and requires further prospective validation. Overall, liquid biopsy represents a promising complementary approach to advance precision oncology and improve lung cancer management.<\/jats:p>","DOI":"10.3390\/cancers18193140","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:57:57Z","timestamp":1790611077000},"page":"3140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology"],"prefix":"10.3390","volume":"18","author":[{"given":"Hicham","family":"Mansour","sequence":"first","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes (UEMF), Fes 30000, Morocco"},{"name":"Laboratory of Molecular Chemistry, Materials and Environment (LCME), Department of Geology, Environment and Health (GES), Faculty of Applied Sciences (FSA), Mohamed 1st University, Nador 62700, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4223-5632","authenticated-orcid":false,"given":"Omayma","family":"Mazouji","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Chemistry, Materials and Environment (LCME), Department of Geology, Environment and Health (GES), Faculty of Applied Sciences (FSA), Mohamed 1st University, Nador 62700, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"El Hammouti","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Chemistry, Materials and Environment (LCME), Department of Geology, Environment and Health (GES), Faculty of Applied Sciences (FSA), Mohamed 1st University, Nador 62700, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihasane","family":"Alloubi","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Mohamed VI University Hospital Center, Tangier 90000, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-8489","authenticated-orcid":false,"given":"Roberto","family":"Incitti","sequence":"additional","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes (UEMF), Fes 30000, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-3571","authenticated-orcid":false,"given":"Sa\u00efd","family":"El Kazzouli","sequence":"additional","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes (UEMF), Fes 30000, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhak","family":"Ouhajjou","sequence":"additional","affiliation":[{"name":"Al Azhar Oncology Center, Rabat 10000, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakib","family":"Nejjari","sequence":"additional","affiliation":[{"name":"Euromed Research Center, Euromed University of Fes (UEMF), Fes 30000, Morocco"},{"name":"Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fes 30070, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"ref_1","unstructured":"(2026, July 08). Absolute Numbers, Incidence, Both Sexes, in 2024. Trachea, Bronchus and Lung. Continents. Available online: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/pie?mode=population&group_populations=0&cancers=15."},{"key":"ref_2","unstructured":"American Cancer Society (2025, October 17). Lung Cancer Survival Rates. Available online: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_3","unstructured":"(2026, July 08). World Health Organization, WHO, Lung Cancer, 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03459846."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.86.1.44","article-title":"Screening for Early Lung Cancer","volume":"86","author":"Melamed","year":"1984","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1158\/1078-0432.CCR-17-1222","article-title":"A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non\u2013Small Cell Lung Cancer and Serum DNA","volume":"23","author":"Ooki","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/joim.13480","article-title":"Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research","volume":"292","author":"Lancaster","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/thx.23.4.414","article-title":"The value of lung cancer detection by six-monthly chest radiographs","volume":"23","author":"Brett","year":"1968","journal-title":"Thorax"},{"key":"ref_8","first-page":"561","article-title":"Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study","volume":"130","author":"Fontana","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., Fagerstrom, R.M., Gareen, I.F., Gatsonis, C., and Marcus, P.M. (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med., 365, 395\u2013409.","DOI":"10.1056\/NEJMoa1102873"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Church, T.R., Black, W.C., Aberle, D.R., Berg, C.D., Clingan, K.L., Duan, F., Fagerstrom, R.M., Gareen, I.F., and Gierada, D.S. (2013). Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med., 368, 1980\u20131991.","DOI":"10.1056\/NEJMoa1209120"},{"key":"ref_11","unstructured":"(2026, July 08). Low-Dose Computed Tomography for Lung Cancer Screening: A Review of the Clinical Effectiveness, Diagnostic Ac-curacy, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 22 September 2015 APPENDIX 8, Guidelines and Recommendations, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK350014\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.chest.2023.10.028","article-title":"ACR Lung-RADS v2022: Assessment Categories and Management Recommendations","volume":"165","author":"Christensen","year":"2024","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"Scholten","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2019.06.009","article-title":"Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening","volume":"118","author":"Pastorino","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ijc.32486","article-title":"Lung cancer mortality reduction by LDCT screening\u2014Results from the randomized German LUSI trial","volume":"146","author":"Becker","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1370\/afm.2582","article-title":"Cancer-Specific Mortality, All-Cause Mortality, and Overdiagnosis in Lung Cancer Screening Trials: A Meta-Analysis","volume":"18","author":"Ebell","year":"2020","journal-title":"Ann. Fam. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.04.035","article-title":"Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography","volume":"134","author":"Sadate","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for Lung Cancer with Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"325","author":"Jonas","year":"2021","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fan, X., Zhong, R., Liang, H., Zhong, Q., Huang, H., He, J., Chen, Y., Wang, Z., Xie, S., and Jiang, Y. (2024). Exhaled VOC detection in lung cancer screening: A comprehensive meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12537-7"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7978","DOI":"10.21037\/jtd-24-1001","article-title":"Collection methods of exhaled volatile organic compounds for lung cancer screening and diagnosis: A systematic review","volume":"16","author":"He","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mansour, H., Nejjari, C., Incitti, R., Anouar, N., and Ouhajjou, A. (2024). Is the development of liquid biopsy for the early detection and the monitoring of breast cancers on its way of overtaking mammography?. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1415940"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): A prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e35823","DOI":"10.1002\/cncr.35823","article-title":"Multicancer early detection testing: Guidance for primary care discussions with patients","volume":"131","author":"Hoffman","year":"2025","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A.B., and Bleckmann, A. (2023). Liquid Biopsies in Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051430"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bjc.6605810","article-title":"Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors","volume":"103","author":"Peng","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rijavec, E., Coco, S., Genova, C., Rossi, G., Longo, L., and Grossi, F. (2019). Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers, 12.","DOI":"10.3390\/cancers12010017"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.21037\/tlcr-24-828","article-title":"The latest advances in liquid biopsy for lung cancer\u2014A narrative review","volume":"13","author":"She","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21037\/atm.2019.03.28","article-title":"Liquid biopsy for lung cancers: An update on recent developments","volume":"7","author":"Revelo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-024-03026-7","article-title":"Liquid biopsy techniques and lung cancer: Diagnosis, monitoring and evaluation","volume":"43","author":"Ren","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13643-025-02860-w","article-title":"Circulating cell-free DNA methylation as biomarker for lung cancer detection: A systematic review and meta-analysis of diagnostic studies","volume":"14","author":"Machado","year":"2025","journal-title":"Syst. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: Opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1038\/s41598-025-88094-1","article-title":"Mutational profiling using liquid biopsy to guide targeted therapy in patients with metastatic cancer","volume":"15","author":"Mazouji","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Urtecho, S.B., Jimenez Munarriz, B., Rabey, M.R., and Leighl, N.B. (2025). Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17213474"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41571-025-01011-3","article-title":"Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: Towards more informative trials","volume":"22","author":"Ernst","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jtho.2023.10.004","article-title":"Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/tlcr-22-742","article-title":"Current and future applications of liquid biopsy in non-small-cell lung cancer\u2014A narrative review","volume":"12","author":"Tomasik","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/j.clon.2024.07.004","article-title":"Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC)","volume":"36","author":"Ospina","year":"2024","journal-title":"Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102791","DOI":"10.1016\/j.ctrv.2024.102791","article-title":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer","volume":"129","author":"Marinello","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.3233\/TUB-220044","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2023","journal-title":"Tumor Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/ejcts\/ezv462","article-title":"Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer","volume":"49","author":"Watanabe","year":"2016","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non\u2013Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhou, F., Qiao, M., Li, X., Zhao, C., Cheng, L., Chen, X., and Zhou, C. (2021). The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.671874"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-017-0536-6","article-title":"The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer","volume":"10","author":"Zhang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/cancers7040874","article-title":"Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges","volume":"7","author":"Luthra","year":"2015","journal-title":"Cancers"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sha, C., and Lee, P.C. (2024). EGFR-Targeted Therapies: A Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216391"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide Frequency of Commonly Detected EGFR Mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5858\/arpa.2023-0536-CP","article-title":"Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation","volume":"148","author":"Sholl","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2019.05.034","article-title":"Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer","volume":"134","author":"Zhang","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdw037","article-title":"Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer","volume":"27","author":"Wilson","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014Implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","article-title":"Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges","volume":"127","author":"Makarem","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: Ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1573398X14666180430144452","article-title":"Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis","volume":"14","author":"Mlika","year":"2018","journal-title":"Curr. Respir. Med. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"srep06269","DOI":"10.1038\/srep06269","article-title":"Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis","volume":"4","author":"Luo","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"869","DOI":"10.17305\/bb.2026.13832","article-title":"A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets","volume":"26","year":"2026","journal-title":"Biomol. Biomed."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:32:24Z","timestamp":1790742744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":71,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193140"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193140","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}